Clinical Outcomes After Intraperitoneal Treatment with 211At-MX35 F(ab′)2
| Time to progression after 211At (mo) | Survival (y) | Time on chemo after 211At (mo) | Number of lines§ after 211At | Admin. total activity (MBq) | Activity concentration MBq/L | Approx. specific activity (no. 211At/mAb) | Effective dose (Sv) |
| 14.1 | 1.7 | 6.5 | 2 | 34 | 22 | 1/2,400 | 0.3 |
| 4.0* | 4.1 | 43 | 6 | 48 | 24 | 1/1,400 | 0.3 |
| 54† | 12.3‡ | 28 | 6 | 40 | 20 | 1/1,800 | 0.3 |
| 5.1 | 5.7 | 46 | 10 | 42 | 21 | 1/700 | 0.3 |
| NA† | 12.1‡ | 92 | 46 | 1/2,100 | 0.6 | ||
| 3.3* | 2.6 | 22 | 4 | 103 | 47 | 1/1,800 | 0.6 |
| 4.0 | 2.3 | 26 | 6 | 119 | 101 | 1/1,500 | 1.3 |
| 3.0 | 2.7 | 21 | 5 | 83 | 73 | 1/2,300 | 0.9 |
| 41.3† | 9.6‡ | 22 | 5 | 65 | 53 | 1/2,900 | 0.7 |
| 5.0* | 2.9 | 14 | 2 | 297 | 180 | 1/500 | 2.3 |
| 3.7* | 1.6 | 14 | 3 | 333 | 203 | 1/200 | 2.6 |
| 9.6† | 4.8 | 36 | 6 | 355 | 215 | 1/200 | 2.8 |
↵* Patients with signs of disease activity at time of therapy.
↵† Patients with longer time to progression after 211At than after chemotherapy regimen given before 211At.
↵‡ Three patients are alive; one (+12 y) with no evidence of ovarian cancer recurrence.
↵§ Total number of chemotherapy regimens given to patients with progressive disease; number is based on individual assessment, resulting in variety of periods on chemotherapy after 211At.
NA = not applicable.